Pathology: breast cancer - adjuvant; es-BC - HER2 positive - (neo)adjuvant (NA); es-BC - HR positive - (neo)adjuvant (NA); la/mBC - HER2 positive - 2nd Line (L2); mBC-Triple negative (TNBC) - 2nd Line (L2); metastatic/advanced - breast cancer (mBC);
| breast cancer - adjuvant | es-BC - HER2 positive - (neo)adjuvant (NA) | es-BC - HR positive - (neo)adjuvant (NA) | la/mBC - HER2 positive - 2nd Line (L2) | mBC-Triple negative (TNBC) - 2nd Line (L2) | metastatic/advanced - breast cancer (mBC) | ||||||||
| KATHERINE, 2019 | ATEMPT, 2021 | KATHERINE, 2019 | Harbeck (TDM-1), 2017 | Harbeck (TDM1 plus ET), 2017 | Harbeck (TDM-1), 2017 | Harbeck (TDM1 plus ET), 2017 | DESTINY Breast03, 2022 | EMILIA, 2012 | ASCENT (patients without brain metastases), 2021 | ASCENT (all population), 2021 | DESTINY-Breast04, 2022 | ||
| trastuzumab emtansine | 5 | T1 | T1 | T1 | T1 | T0 | T1 | ||||||
| trastuzumab emtasine plus endocrine therapy | 3 | T1 | T1 | T1 | |||||||||
| trastuzumab deruxtecan | 2 | T1 | T1 | ||||||||||
| sacituzumab govitecan | 2 | T1 | T1 | ||||||||||
| chemotherapy | 0 | T0 | |||||||||||
| trastuzumab based treatment | 0 | T0 | |||||||||||
| Standard of Care (SoC) | 0 | T0 | T0 | ||||||||||
| trastuzumab | 0 | T0 | T0 | ||||||||||
| trastuzumab plus endocrine therapy | 0 | T0 | T0 | T0 | T0 | ||||||||
| lapatinib plus capecitabine | 0 | T0 | |||||||||||